Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Paclitaxel-Coated Balloons Against Drug-Eluting Bioresorbable Scaffolds for Elective PCI Using OCT

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* written consent~* indication for elective PCI of a de novo coronary stenosis in a native vessel~* coronary multivessel disease with clinically proven indication for repeating coronary angiography at 6-9 months (staged PCI strategy)~Exclusion Criteria:~* pregnancy, lactation, women of childbearing age w/o reliable contraception~* life expectance \< 50 % at 1 year~* major surgery planned within 6 months~* participation in other clinical trials or impossibility to give written consent~* acute coronary syndrome or cardiogenic shock within the last 4 weeks~* stent thrombosis, defined as probable or definite by ARC~* contraindication against dual antiplatelet therapy~* allergy against mTOR-inhibitors or taxol derivates~* target lesion situated in the left main coronary artery, in a bypass graft or a grafted vessel~* reference luminal diameter of the target lesion \> 3.75 mm or \< 2.0 mm~* lesion length \> 30 mm, bifurcation lesion requiring intervention on a major side branch

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- BRS (Type: ACTIVE_COMPARATOR): OCT-guided BRS implantation: implantation of a bioresorbable scaffold (BRS) under OCT guidance.~Note: Absorb™ from Abbott Vascular has been used as BRS until this product became unavailable in April 2017. Currently the recruitment is stopped due to this issue, until the use of another BRS gets final approval.
- DCB-only (Type: EXPERIMENTAL): FFR-guided DCB-only PCI: PCI using DCB (SeQuent Please™, B Braun Melsungen GmBH) without stent implantation und FFR guidance

Based on this trial design, predict the completion outcome and termination type (if applicable).